polycyctic ovarian syndrome. Polycystic ovarian syndrome
Conditions
Interventions
Intervention 1: Intervention group: Antioxidant MitoQ10 includes Mitoquinol (as Mitoquinol Mesylate) also cantains Microcrystallin Cellulose, Tapioca and silicon dioxide, 40 mg per day, for 6 weeks, o
Treatment - Drugs
Placebo
Intervention group: Antioxidant MitoQ10 includes Mitoquinol (as Mitoquinol Mesylate) also cantains Microcrystallin Cellulose, Tapioca and silicon dioxide, 40 mg per day, for 6 weeks, oral capsule, Mit
Control group: Pelacebo khown as vegetable capsule contains Microcrystallin Cellulose, Tapioca and silicon dioxide, 40 mg for 6 weeks, MitoQ Ltd.
Sponsors
Tehran University of Medical Sciences
Eligibility
Sex/Gender
Female
Age
18 Years to 40 Years
Inclusion criteria
Inclusion criteria: Patients with polycystic ovarian syndrome which its diagnosis is based on the Rotterdam ESHRE/ASRM criteria (Rotterdam ESHRE/ASRMcriteria 2004) are included in this study.
Exclusion criteria
Exclusion criteria: Exclusion criteria: basal FSH >10 IU/L; treatment with estrogen–progestin and/or other hormonal therapies in the six months before the study; in the presence of ovarian cysts with a diameter gre14 mm observed in two ultrasound examinations conducted within thirty days of each other; endometriosis; genetic and/or autoimmune aberrations; chronic liver disease; chronic systemic inflammatory diseases; hyper- and hypo-adrenal cortical diseases; type 2 diabetes mellitus; intolerance to carbohydrates; presence of a single ovary; and previous ovarian surgery.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| TRX gene and protein expression. Timepoint: After 6 weeks intervention. Method of measurement: Western Blot, RT-PCR.;TXNIP gene and protein expression. Timepoint: After 6 weeks intervention. Method of measurement: Western Blot, RT-PCR.;ASK1 gene and protein expression. Timepoint: After 6 weeks intervention. Method of measurement: Western Blot, RT-PCR.;Oocyte number. Timepoint: After 6 weeks intervention. Method of measurement: microscope.;Embryo number. Timepoint: After 6 weeks intervention. Method of measurement: microscope.;Embryo quality. Timepoint: After 6 weeks intervention. Method of measurement: microscope.;Oocyte quality. Timepoint: After 6 weeks intervention. Method of measurement: microscope. | — |
Secondary
| Measure | Time frame |
|---|---|
| Pregnancy rate. Timepoint: after intervention. Method of measurement: B-HCG Test. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactElnaz Salahi
Tehran University of Medical Sciences
Outcome results
None listed